Ibrutinib effective in elderly patients with CLL


Researchers from the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), along with those from MD Anderson Cancer Center will be presenting interim findings at the June meeting of the American Society of Clinical Oncology of a Phase I/II clinical trial evaluating the experimental drug ibrutinib (PCI-32765).

The trial evaluated the oral drug ibrutinib (PCI-32765) in the treatment of elderly patients with chronic lymphocytic leukemia (CLL).

The interim findings suggest that ibrutinib has a low toxicity profile with few side effects but a high response rate in the older patient population. Typically these patients receive fludarabine, which causes many side effects and can quickly become useless as resistance builds.

CLL is the most frequently diagnosed form of leukemia, accounting for over 16,000 new cases in the US annually, and between 4000 and 5000 people die from CLL each year.

Source: Medical News Today

LymphomaInfo Social